The result indicated that treatment with the anti-PD-L1 antibody alone indeed suppressed tumor growth; however, tumor growth inhibition was further enhanced by the combination of this antibody with in situ injection of the PD-L1-SARS peptide vaccine (Fig. 4A and B). This evidence concerns the gene CD274 and neoplasm.